Carla Pecora

Dr. Carla Pecora

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Toxins
Verified
Journal Article
Open access
PDF file
CPCarla Pecora
Carla Pecora
DSDanielle Shitara
Danielle Shitara
Unilateral peripheral facial nerve palsy jeopardizes quality of life, rendering psychological consequences such as low self-esteem, social isolation, anxiety, and depression. Among therapeutical approaches, use of Botulinum toxin type A (BoNT-A) on the nonparalyzed side has shown promising results and improvement of quality of life. Nevertheless, the correct technique is paramount, since over-injection of the muscles can result in lack of function, leading to a “paralyzed” appearance, and even worse, functional incompetence, which may cause greater distress to patients. Therefore, the objective of this article is to provide a practical guideline for botulinum toxin use in facial palsy. To this aim, adequate patient assessment, BoNT-A choice, injection plan and dosage, and injection techniques are covered.

1 September 2021 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
JLJani van Loghem
Jani van Loghem
SSSonja Sattler
Sonja Sattler
GCGabriela Casabona
Gabriela Casabona
SCSebastian Cotofana
Sebastian Cotofana
SFSabrina Guillen Fabi
Sabrina Guillen Fabi
TPTatjana Pavicic
Tatjana Pavicic
Background: As the treatment indications for the Cohesive Polydensified Matrix® hyaluronic acid (CPM-HA) portfolio continue to expand and diversify, injectors new to the range or those who are expanding the treatments they offer may be unsure of the optimal product and injection technique for specific facial areas. Each product in the CPM-HA portfolio has been intentionally designed to provide the best physical properties for a specific indication and target tissue. This document has been developed to provide a comprehensive, one-stop reference for clinicians using the portfolio. Methods: An international panel of experts in the field of aesthetic medicine convened to develop guidelines on effective and safe injection technique when performing treatments with the CPM-HA range of soft-tissue fillers. Results: Consensus members considered treatment indications in the upper, middle and lower face. Landmark deficiencies and anatomical considerations are described for each indication and consensus recommendations provided on the optimal product, injection depth and treatment technique. This is supplemented by the experts advice on avoidance of complications. Throughout, an evidence-based approach to selection of products and injection techniques is provided. The result is a fully tailored approach to a range of indications covering the full portfolio of CPM-HA products, including the newest addition for skin revitalization. Conclusion: The recommendations in this consensus document are provided to assist clinicians in the selection of CPM-HA products, administration techniques and depths of injection with the aim of providing seamless and natural treatment results, enhanced safety and patient satisfaction.

1 February 2021 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
CPCarla Pecora
Carla Pecora
MPMaria Valéria Bussamara Pinheiro
Maria Valéria Bussamara Pinheiro
KFKarin Ventura Ferreira
Karin Ventura Ferreira
GNGisele Jacobino de Barros Nunes
Gisele Jacobino de Barros Nunes
HMHelio Miot
Helio Miot
Purpose: Botulinum toxin type A is an effective treatment for glabellar dynamic wrinkles. As the muscular group involved in the contraction of the glabella varies among people, individualized treatment can achieve optimal results. This study evaluates a customized assessment for the treatment of glabellar lines with Incobotulinumtoxin-A, leading to an individualized points distribution and dosage. Patients and Methods: A single-center, evaluator-blinded, therapeutic cohort study enrolled 130 women with moderate or severe glabellar wrinkles. They underwent Incobotulinumtoxin-A injection following the standard 5-point injection at the glabellar muscles (n = 65) or an individualized assessment and scheme treatment based on anatomical references of contraction, the One21 technique (n = 65). All the patients were photographed under maximum contraction before treatment (T0) and after 4 weeks (T28). The photos were randomly assessed by two blinded, experienced raters to consensually grade the severity according to the Merz Aesthetics Scales (MAS). The primary clinical efficacy was defined as a 2-point reduction in the MAS score, on Day 28. Results: The groups were homogeneous regarding age, phototype, and baseline MAS scores. On Day 28 (T28), 64 (98.5%) patients from the One21 group and 52 (80%) from the 5-point group reduced the MAS score by at least two points (p < 0.01). When adjusted by age and phototype, both groups reduced the MAS score at T28 (p < 0.01); nevertheless, patients from the One21 group significantly performed better (p < 0.01), with a much higher rate response rate at T28, in comparison to the 5-point group. Of patients enrolled in the 5-point group, 83.1% utilized muscle groups other than the procerus and corrugator in glabellar wrinkle formation, and 17 (24.6%) presented asymmetrical contraction. Patients from the 5-point group with glabellar asymmetry and those who utilized the frontalis and orbicularis presented inferior performance (p < 0.05), reinforcing the importance of an individualized assessment and treatment plan. Conclusion: The One21 technique yielded better results than the standard 5-point treatment in reducing glabellar dynamic lines with Incobotulinumtoxin-A, especially for asymmetric lines of the glabella or the involvement of muscle groups other than the procerus and corrugator.

1 February 2020 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
CPCarla Pecora
Carla Pecora
It is well known that incobotulinumtoxinA (INCO) is an effective approved treatment for dynamic wrinkles of the upper face caused by the action of mimetic muscles over time. In doing so, it is important to maintain a balance between muscle groups and a natural facial appearance. Patients differ enormously in their facial anatomy regarding structure and function, both within and between genders, ethnicities, and age. Therefore, treating all patients with the same injection pattern and the same doses can result in undesired outcomes. There is a need for a tailored approach to achieve optimal results, as well as to increase patient satisfaction. With this in mind, the novel one21 injection technique which allows for individualized treatment has been developed for the treatment of horizontal forehead lines using INCO, resulting in a positive impact on eyebrow position and shape. This technique is the next step in a customized approach, giving natural-looking results and high patient satisfaction.

2 April 2024 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
CPCarla Pecora
Carla Pecora
Background: The signs of aging seem to be more visible on the neck compared to other locations, especially if a patient has already gone through facial rejuvenation procedures. Treatment of the aging neck imposes a challenge to the clinician, since one single approach is usually not enough to achieve the desired result, requiring multiple injections and sessions, which apart from being painful for the patients, is time‐consuming for the clinician.Aim: To describe the use of calcium hydroxyapatite, incobotulinum toxin type A and Cohesive poly‐densified matrix hyaluronic acid diluted in the same syringe and injected in the same session for neck rejuvenation.Patients and Methods: Fifteen women, older than 18 years, with cervical skin flaccidity grade 1–4 in a previously validated 5‐point rating scale (Dermatologic Surg, 2016; 42, S94), who sought neck rejuvenation were injected in this pilot study with a single session with a combined hybrid mixture of calcium hydroxyapatite, incobotulinum toxin type A, and Cohesive poly‐densified matrix hyaluronic acid and followed up for 90–180 days.Results: At the 4‐month post injection evaluation, 93.3% of the patients presented at least 1‐grade improvement in the 5‐point scale as evaluated by the investigator. No serious adverse events were reported, being most mild and transient in nature.Conclusion: CaHA, incoBonTA, and CPM‐HA have complementary mechanisms of action and may be injected from the same syringe in the same session, boosting the final outcome, with high patient satisfaction, and ease of process for both patients and clinicians.

1 June 2025 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
CPCarla Pecora
Carla Pecora
NCNiamh Mbbs Corduff
Niamh Mbbs Corduff
JCJulia Md Carroll
Julia Md Carroll
MMMariana Muniz
Mariana Muniz
SSSonja Sattler
Sonja Sattler
Background: Facial aging is a complex process that varies by facial layer and patient characteristics. Correction of the signs of facial aging can be achieved with various aesthetic treatments, including Cohesive Polydensified Matrix hyaluronic acid (CPM-HA), calcium hydroxylapatite in carboxymethylcellulose (CaHA-CMC), microfocused ultrasound with visualization (MFU-V), and incobotulinumtoxinA (incoBoNT-A). This article describes how these treatments can be used in an individualized, layered approach for whole-face rejuvenation that optimizes outcomes and patient satisfaction. Methods: An international panel of 5 expert aesthetic physicians convened to align on best practices for a layered approach to whole-face rejuvenation using CPM-HA, CaHA-CMC, MFU-V, and incoBoNT-A. Panelists reviewed statements about facial aging and key features of the select products supporting their use in a layered treatment plan. Results: The proposed layered treatment plan expands on previous work by de Sanctis Pecora and consists of targeting (1) bone and retaining ligaments; (2) muscles, ligaments, and the superficial muscular aponeurotic system; (3) fat pads; (4) the dermis; and (5) skin quality. Panelists agreed that key features of the select products inform their positioning in the layered treatment plan. Step-by-step procedures for targeting each layer—including product, injection or application technique, and/or rationale—are provided. Conclusions: CPM-HA, CaHA-CMC, MFU-V, and incoBoNT-A are considered by the expert panel of aesthetic physicians to be ideal treatment options to obtain a synergistic effect in layered whole-face rejuvenation.